Solid organ transplant recipients are at high risk of @entity364 , because of ongoing immunosuppressive treatment. There are three post organ transplant phases: early, intermediate, and late, all of them at risk of @entity6923 . Since conventional tests are insufficient, specific secondary diagnostic tests are still being explored. Serological tests are currently the most common choice. The present study was to determine the usefulness of mannan antigen and anti-mannan antibody detection in diagnosing @entity8 . The levels of mannan and anti-mannan antibodies were assessed with Platelia Candida Ag Plus, and Platelia Candida Ab Plus (Biorad, Marne-la-Coquette, France) commercial tests, according to manufacturer's guidelines. Sixty six serum samples were obtained from 25 @entity1 (9 liver transplant recipients, 7 kidney transplant recipients, and 9 @entity1 prepared for a kidney transplant), 29 serum samples from 15 @entity1 tested positive for mannan antigen. Serum samples were obtained from 14 @entity1 tested positive for anti- mannan antibodies. Fungal antigen detection in blood serum in @entity1 under immunosuppression, especially with @entity1398 , suggests that antifungal treatment should be administered. Serological tests, especially mannan and anti-mannan ones, are very useful for confirmation or exclusion of @entity3 in high-risk @entity1 .

XXXX serological diagnosis in solid organ transplant recipients.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['invasive candidiasis in liver or kidney transplant recipients'] @entity6923 :: ('MESH:C536777', 'Disease') :: ['Candida infections'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal infections'] @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive candidiasis']
@entity3 :: (MESH:D009362,Disease) :: ['Invasive candidiasis']
